Results 291 to 300 of about 103,365 (348)

The estrous cycle moderates the food and body weight suppressive effects of glucagon-like peptide-1 receptor agonism. [PDF]

Diabetes Obes Metab
Applebey SV, Xiao AG, Reiner BC, Hayes MR.   +3 more
europepmc   +1 more source

Characteristics and outcomes of cubital tunnel decompression in diabetic patients receiving glucagon-like peptide-1 receptor agonists. [PDF]

Clin Shoulder Elb
Shabbir R, Shamith S, Parente PEL, Nicholson L, Ali A.   +4 more
europepmc   +1 more source

Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Clin Transl Gastroenterol
Garg S, Hoxha D, Long D, Valencia S, Yang Q, Lembo A, Vargo JJ, Chiang DJ.   +7 more
europepmc   +1 more source

Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity.

JAMA Netw Open
Li P, Varghese JS, Shah MK, Galindo RJ, Pasquel FJ, Ali MK, Shao H.   +6 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Pay-Per-Click Direct-to-Consumer Advertising.

JAMA Netw Open
Eisenkraft Klein D, Zenone M, Kesselheim AS.   +2 more
europepmc   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on ischemia/reperfusion injury in isolated hearts of rats with metabolic syndrome

Ravić, Marko
openalex   +1 more source